CC
NVO

Capital Counsel’s Novo Nordisk NVO Stock Holding History

Capital Counsel’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,541
Closed -$219K – 58
2024
Q4 		$219K Hold
2,541
– – 0.01% 52
2024
Q3 		$303K Buy
2,541
+41
+2% +$5.47K 0.01% 45
2024
Q2 		$357K Hold
2,500
– – 0.02% 40
2024
Q1 		$321K Hold
2,500
– – 0.01% 44
2023
Q4 		$259K Hold
2,500
– – 0.01% 46
2023
Q3 		$227K Hold
2,500
– – 0.01% 49
2023
Q2 		$202K Buy
+2,500
New +$204K 0.01% 51

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Capital Counsel's NVO Position: Q1 2025 in Review

Capital Counsel sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 2,541 shares — an estimated $219K sold.

Capital Counsel first reported a position in NVO in Q2 2023 and held it in 7 quarters. The position peaked at $357K in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Capital Counsel reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Capital Counsel sold 2,541 Novo Nordisk shares in Q1 2025, an estimated $219K.
  • Capital Counsel first reported a position in Novo Nordisk in Q2 2023 and held it in 7 quarters.
  • Capital Counsel's Novo Nordisk position peaked at $357K in Q2 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Capital Counsel's 13F filing for Q1 2025, filed 14 May 2025.